Ketryx relies on a combination of continuous validation, testing, and human oversight to ensure the platform remains compliant and reliable as AI capabilities evolve, CEO Kaminski said.

Under the deal, Monogram shareholders will receive $4.04 per share in cash, plus a contingent value right (CVR) that could deliver up to $12.37 per share in additional payments if milestone targets are achieved by 2030.

Quest is actively building collaborations with academic and pharmaceutical partners to integrate Haystack MRD into clinical investigations. These partnerships are not yet public but span multiple tumor types and therapeutic areas, VP Dan Edelstein said.

Roche Diagnostics, Intuitive Surgical, Abbott and Edwards Lifesciences all acknowledge tariff headwinds, but stress preparedness, resilience and mitigation. Below is look at how management framed the impact in Q1 vs Q2 earnings calls.

With $7.6m in funding, Qbeast plans to allocate about 55% of resources to engineering and R&D, 25% to go-to-market partnerships, sales, and marketing, 10% to customer success and onboarding and the remaining 10% to internal platform and operations to support scaling.

BD raised its adjusted earnings per share guidance midpoint by $0.18 to a range of $14.30 to $14.45, representing growth of about 9.4% at the midpoint – an increase of approximately 1.4% over prior guidance.